Introduction: 21
Bone marrow primarily comprises hematopoietic cells embedded in supporting stroma. The latter 22 also houses specialized precursors. First evidence for the presence of non-hematopoietic progenitors 23 in bone marrow was put forward more than 140 years ago by the German pathologist Julius Friedrich 24
Cohnheim ; he was the first to notice the occurrence of "mesenchymal precursor cells" 25 there (Cohnheim, 1867) . This observation was affirmed not until 1970, when Alexander Friedenstein 26 specified these particular cells in culture as firmly adhering to the surface of culture dishes and vastly 27 forming colonies (Friedenstein, Chailakhjan, & Lalykina, 1970) . Besides self-renewal potential, this 28 cell type also exhibited multipotential differentiation capacity, and thus two decades later, Arnold 29
Caplan coined the term of the "mesenchymal stem cell" (Caplan, 1991) . As of now the biological 30 attribution "mesenchymal stem cell" is still debated for at least in the embryo myogenic and the 31 skeletal tissue do not share a common primordial precursor (Paolo Bianco, 2011) 32 In the early days, the heterogeneity of the non-hematopoietic cell isolates made it difficult to 33 precisely specify single, distinct entities in the bone marrow and other stromal tissues representing 34 specific mesenchymal precursors. Thus besides MSCs, other names were introduced by various 35 research teams, e.g. "multipotent adult progenitors cells" (MAPCs), "marrow-isolated adult 36 multilineage inducible cells (MIAMIs), or "very small embryonic-like stem cells" (VSELs) (Asahara et 37 al., 1999; D'Ippolito et al., 2004; Y. Jiang, 2002; Kronenberg & Schipani, 2009; Reyes et al., 2001 ). In 38
2006, a group of peers in the field acting under the auspices of the 'International Society for Cellular 39 Therapy' refined the minimal criteria for multipotent stromal cells: firstly MSCs should exhibit strong 40 attachment to the surfaces of culture dishes (plastic adherence), secondly MSCs have to bear a set 41 of, albeit not unique, surface markers such as CD90, CD73, CD105, CD146, CD44 while at the same 42 time lacking the expression of CD34 and CD45, CD31, CD11b, CD14 and CD19, CD79α as well as HLA-43 chronic inflammatory insults during enduring tendonitis, tendinosis, bursitis, or epicondylitis 119 eventually resulting in tendon rupture. 120
Besides the use of growth factors, cytokines or gene therapy, the field of tissue engineering based on 121
MSCs is vastly emerging (Longo, Lamberti, Maffulli, & Denaro, 2010) . Despite well-established 122 surgical procedures and subsequent therapeutic regimens, MSCs are today considered an interesting 123 option for tendon regeneration, and therefore MSC-based applications are presently being studied in 124 humans, rabbits, rats and horses (Violini, 2009) . 125
Interestingly, there is no commonly accepted standardized recipe to convert naïve MSCs into 126 tenogenic precursors. Moreover, no reliable protocols have been established for differentiation of 127
MSCs into tenocytes. Members of the bone morphogenetic protein (BMP) and the transforming 128 growth factor (TGF) superfamily as well as fibroblast-like growth factors (FGF) have been tested (for a 129 recently published comprehensive review see Longo et al., 2010) . Exceptionally, rat bone marrow 130
MSCs can be stimulated in vitro by BMP-12 to differentiate along the tenogenic lineage (Lee et al., 131 2011 ). This finding is strengthened by the observation that BMP-12 pretreated MSCs improved 132 tendon healing in a calcaneal tendon defect. More than a decade ago, experimental attempts have 133 been commenced by loading scaffold material with MSCs prior to transplantation. The material 134 composed of a pretensioned polyglyconate suture was first cellularized with synovium-derived MSCs 135 and thereafter grafted into an iatrogenically introduced, 1-cm Achilles tendon gap in a rabbit. This 136 resulted in regeneration with well-organized collagen fibers and enlarged cross-sectional areas within 137 the defect (Young et al., 1998) . Since then, both direct delivery of MSCs, or engraftment of MSCs in 138 combination with biomatrices have been thoroughly investigated in more than 20 published studies 139 (see Table 1 ). One particular study yielded important results: when loading increasing numbers of 140 bone marrow-derived MSCs (1, 4 and 8 million of rabbit MSCs/ml) onto collagen gels, those defects 141 that contained MSC-collagen scaffolds showed indeed much higher maximum stresses and moduli 142 compared to natural healing defects, but the increasing cell numbers showed no distinct differences 143 with regard to organization of the regenerated tissue or matrices (Awad et al., 2003) . This 144 observation raised the question how MSCs contribute to tendon healing and regeneration, in 145 particular whether the delivered MSCs are actually dominantly influencing wound healing and 146 regeneration through secreted factors. In this context it is also important to note that MSCs show 147 beneficial long-term effects in the course of tendinitis. In an equine flexor digitorum superficialis 148 tendon model of collagenase-induced bilateral tendinitis lesions, bone marrow-derived MSC 149 treatment induced no aberrant tendon-specific marker expression such as collagen I or III, insulin-like 150 growth factor, cartilage oligomeric matrix protein, matrix metalloproteinases and aggrecanase-1. Yet 151 those tendons treated with MSCs showed indeed improved histological scores (Schnabel et al., 152 2009), again raising the up till now insufficiently answered question what are the molecular 153 mechanisms that govern this effect. Due to these results, regeneration of ruptured or damaged 154 tendon tissue has received a lot of interest in veterinary medicine, with the greatest resonance in 155 equine orthopedics. To treat tendon injuries in horses, marrow cells are now often explanted from 156 the sternum, and re-implanted into the damaged tendon tissue (Richardson, Dudhia, Clegg, & Smith, 157 2007) . 158
Addressing age-related tendon pathology, effectiveness of MSCs has been investigated in 159 regeneration of the enthesis, the site where tendon attaches to the bone. Often this part 160 degenerates with increasing age leading to mobility failures. In comparison to delivery of 161 chondrocytes, MSCs treatment strongly enhanced regeneration of the enthesis actually resulting in 162 morphological and biomechanical properties similar to those of a normal enthesis morphology and 163 function (Nourissat et al., 2010) . 164
165

Bone and cartilage 166
In many aspects of orthopedics, bone and cartilage regeneration after trauma and tumor surgery, as 167 well as in the geriatric patient are of increasing relevance since molecular mechanisms which had 168 been elucidated by means of experimental osteologic and biogerontologic research are being 169 translated into innovative technology and medical applications. Just about endless individual 170 approaches in the recent decades have led to improved implant materials to be used in the clinics, as 171 well as bioactive factors with proven efficacy, and MSCs combined with biomaterial and bioactive 172 factors emerged as a powerful additional concept of enhancing bone formation in degenerated or 173 injured tissues. Successful cell-based bone tissue engineering has been reported for isolated MSCs 174 from bone marrow, followed by in vitro cultivation and expansion before seeding plastic adherent 175
MSCs onto porous scaffold material in a 3D culture system (P. Bianco & Robey, 2001) . Many 176 laboratories have demonstrated that MSCs, when being loaded on hydroxyapatite scaffolds and 177 implanted into NOD/SCID mice are capable of generating functional bone tissue (Krebsbach et al., 178 1997) . Besides hydroxyapatite other natural or synthetic material has been tested to serve as 179 innovative scaffolds such as plant-derived material, collagen type I, tri-calcium phosphate ceramics, 180 or poly-DL-lactic-co-glycolic acid (PLGA) (Cancedda, Dozin, Giannoni, & Quarto, 2003) . For treatment 181 of osteogenesis imperfecta, a genetic bone disorder, bone marrow-derived MSCs have been infused 182 whichfunctionally improved bone and cartilage formation (Pereira et al., 1995) . Also an 183 experimentally set traumatic alveolar bone defect in the maxilla of Sprague-Dawley rats could be 184 successfully treated with non-pre-osteoinducted bone marrow-derived MSCs actually yielding 185 considerably higher bone formation (Zhang et al., 2002) . Most tempting were results challenging the 186 immune modulatory potential of bone marrow-derived MSCs, as application resolved severe 187 inflammation at the implantation site of ceramic ankle prosthesis, or in cases of aseptic loosening of 188 the total ankle arthroplasty (Ohgushi & Caplan, 1999) . 189
Bone is continuously remodeled by a concerted action of osteoclasts responsible for bone resorption, 190 and osteoblasts accounting for osseous growth. Thus due to the ability of MSCs to form osteoblasts, 191
MSCs have early on been tested in bone regeneration studies. Osseous healing features but one 192 particular interesting result, which is scarless functional bony tissue. A commonly used method to 193 investigate bone regeneration is the so-called 'critical size defect', which when left alone shows 194 insufficient ossification (Schmitz & Hollinger, 1986) . Employing this approach as a by now commonly 195 accepted standard to investigate defect healing, rapid progress has been achieved in the previous 196 decades (Fröhlich et al., 2008) . Ectopic implantation of sheep bone marrow-derived MSCs loaded on 197 a hydroxylapatite carrier into a critical size defect within long bone improved bone formation and 198 healing to a much higher content when compared to controls (Kon et al., 2000) . 199
In conjunction with cell-based approaches emphasis has been put on the quickly translate cell-based 200 skeletal tissue engineering strategies to the bedside (for a recent review see Panetta, Gupta, & 201 Longaker, 2010) . 202
Similarly, regenerative methods for cartilage repair have been introduced in the clinic in 1999 by 203 performing autologous chondrocyte transplantation (Brittberg, 1999) . By the same token, the 204 application of MSCs for cartilage regeneration is an evolving field. Many attempts have been 205 undertaken applying MSCs after forced in vitro chondrogenic differentiation and subsequent seeding 206 of the precursors onto specific scaffold materials prior to engraftment into cartilage defects. 207
Interestingly, when filling a cartilage defect for just 10 minutes with synovium-derived MSCs, enough 208 cells appear to settle in thereby resulting in efficient cartilage regeneration. Due to this type of 209 unsophisticated application, i.e. without preceding periosteal coverage of the wound and no further 210 use of scaffold material, this low-invasive method appears most promising (Koga et al., 2008) . 211
212
Heart 213 Heart failure is often fatal. Presently, myocardial infarction is the most common cause for heart 214 failure with highest prevalence in the western societies. Heart is also thought to exhibit least 215 regenerative potential as growth of new vessels within infarcted areas appears to be greatly 216 suppressed and cardiomyocytes are supposedly arrested in the cell cycle after development. This 217 paradigm is shifting, and the myocardium is currently being targeted by various regeneration 218 strategies (Choi et al., 2010) . Adult progenitor and stem cell treatment of diseased human 219 myocardium has been carried out for more than 10 years (Menasche et al., 2001) . Since then various 220 precursor types and cells have been employed in studies in humans. Notably, hematopoietic stem 221 cells or endothelial progenitor cells, although yielding considerable angiogenic effects, showed no 222 satisfying results (Stamm, Nasseri, Choi, & Hetzer, 2009) . Working along similar lines, MSCs and 223 related cell types have been evaluated in preclinical models of disease as well as in more than 20 224 clinical trials, which employed adult stem cells (bone marrow stem cells, mobilized peripheral blood 225 stem cells and skeletal myoblasts) for treatment (Wollert & Drexler, 2010) . Thoroughly studied to 226 date is also therapeutic treatment with MSCs. A general consensus from these trials is that MSCs or 227 blood-derived stem cells do not replenish lost cardiomyocytes or vascular cells, yet it is the powerful 228 paracrine effect of MSCs, which prevailingly acts on the heart tissue that triggers beneficial effects of 229 tissue regeneration (Lai, Chen, & Lim, 2011) . 230 231
Spinal cord injury 232
Severe trauma of the spinal cord may lead to functional impairment of nervous tissue, in particular 233 structural damage of axons resulting in demyelination, and clinical consequences for patients who 234 suffer from severe spinal cord injury (SCI) is partial or complete loss of motor and sensor function. 235
Regeneration and functional restoration after SCI (Callera & do Nascimento) only rarely occurs as 236 glial scar formation takes place driven by non-permissive environmental circumstances of enduring 237 and overly prevailing inflammatory responses, and not to forget the fatal lack of neurogenic 238 supporting factors in adult tissues. In the US, there are approximately 12,000 new patients per year 239 who contract SCI, mostly as a result of physical injury accompanied with inflammation (Ichim et al., 240 2010) . Currently there is no efficient treatment for SCI. 241
In this context MSCs could be turned into neurogenic precursors which express specific neuronal 242 markers in vitro (Delcroix, Curtis, Schiller, & Montero-Menei, 2011; Deng, Petersen, Steindler, 243 Jorgensen, & Laywell, 2006) . After engraftment into rats, these precursors formed bundles of 244 neurofilament-positive fibers in scar tissues (Hofstetter et al., 2002) . Currently MSC-based 245 approaches are tested to warrant survival and remyelination of axons (Wright, El Masri, Osman, 246 Chowdhury, & Johnson, 2010) . 247
Also the immunosuppressive effects of MSCs are considered benevolent, in particular as they are 248 thought to cease the characteristic symptoms of SCI by settling the inflammatory response, which in 249 due course should reduce cavity formation and demyelination (Uccelli, Benvenuto, Laroni, & Giunti, 250 2011) . In spite of future expectations and promising vistas, only vague anticipations have been 251 gained of whether MSCs perform salubrious after transplantation into patients suffering from SCI 252 (Ichim et al., 2010) . It remains to be shown whether bone marrow-derived MSCs exhibit sufficient 253 neurogenic transdifferentiation capacity in vivo, and whether they show high enough survival rates 254 within the transplantation sites (Wright et al., 2010) . 255
The dog is the most frequently used, and presumably also most appropriate animal model to 256 investigate SCI. The "Olby scoring system" allows a highly accurate analysis of regeneration and 257 recovery of damaged axons (Olby et al., 2001) . Working along this line, the performance of 258 autologous and allogenic MSCs has been evaluated in the SCI healing process. Notably, autologous 259 bone marrow-derived MSCs showed improved functional recovery after SCI compared to allogenic 260 cells (Jung et al., 2009 ). The interpretation of this finding is tempting as it is likely that it is more than 261 the paracrine factors, which are produced by MSCs, playing a critical role: it is highly likely that MSC 262 progeny exert the beneficial effect through integration into reconstituting nervous tissue. Also other 263 animal models have been employed as experimental models in order to improve MSCs application to 264 cure SCI, for instance to investigate different delivery methods of MSCs (Table 2) . In a rat model 265 undergoing a subtotal hemisection at cervical level 4, human bone marrow-derived MSCs have been 266 grafted after SCI in order to specify the most efficient way of transplantation. In this study delivery 267 via lumbar puncture compared superior over intravenous injection or the commonly used method of 268 direct injection (Paul, Samdani, Betz, Fischer, & Neuhuber, 2011 ). An interesting way of improving 269 regeneration of SCI is electrical stimulation or electrical acupuncture to invoke permissive 270 physiological signals for the recovery of damaged nerve tissue, i.e. applying spike waves, resulted in 271 improved functionality and recovery in SCI rats by increasing the survival rate of the implanted bone 272 marrow-derived MSCs (Wu et al., 2011) . 273
It is generally believed that a very important factor in regenerating damaged neurons and axons is 274 the action of neurotrophic factors secreted by MSCs (Wright et al., 2010) . The role of neurotrophin 3 275 (NT-3) was investigated in this context using human umbilical cord MSCs overexpressing this 276 bioactive molecule (Shang et al., 2011) . In rats, NT-3 secreting MSCs brought about improved 277 locomotor function and myelination. Furthermore, the neuropeptide pituary adenylate cyclase 278 activating polypeptide (PACAP) is known to trigger cAMP production actually not only controlling 279 axonal regeneration but also neurogenesis and protection. A combinatorial therapy of immortalized 280 human MSCs and PACAP was thus performed (Fang et al., 2010) . In vitro analysis on neurologic 281 differentiation revealed a positive effect on neurodifferentiation when exposing human MSCs to 282 PACAP and other neurogenic factors, such as dbcAMP, β-mercaptoethanol and retinoic acid. Notably 283 in SCI rats, hind limb functionality greatly improved, which ranks this particular way of thinking and 284 experimentation high in continuation of optimizing future strategy in this field. 285
286
Neurological disorders 287
MSCs are also considered potential assets for other neurological disorders. Multiple system atrophy 288 (MSA) is paralleled by degeneration of nerve cells in specialized brain tissue, and thus besides 289 movement and balance disorders MSA patients suffer also from a combination of autonomic failures. 290
Intravenous infusion of GFP-tagged MSCs in a transgenic MSA mouse model resulted in protection of 291 dopaminergic neurons in the substantia nigra pars compacta and also ameliorated 292 neuroinflammation in this area (Stemberger et al., 2011) . The potential of MSCs in the treatment of 293 experimental autoimmune encephalomyelitis (EAE), a model for human multiple sclerosis has also 294 been exploited (Uccelli et al., 2011) . Intravenous infusion of bone marrow-derived MSCs improved 295 the clinical course of EAE (Gerdoni et al., 2007; Zappia et al., 2005) . In this model, the injected MSCs 296 firstly induced peripheral T cell tolerance to myelin proteins resulting in reduced migration of 297 pathogenic T cells to the CNS, and secondly and most notably, also homed themselves to the CNS 298 where they protected axons and stalled demyelination. In a later study, adipose-derived MSCs 299 demonstrated pronounced therapeutic potential following a bimodal mechanism by which the 300 autoimmune response was greatly suppressed in early phases of disease, while in animals with 301 established disease local neuroregeneration by endogenous progenitors was stimulated only later 302 (Constantin et al., 2009 ). Bone marrow-derived MSCs were also tested in an animal model 303 resembling Parkinson's disease thereby exerting neuroprotection on 6-hydroxydopamine-exposed 304 dopaminergic neurons supposedly enforcing anti-apoptotic mechanisms (Wang et al., 2011) . In the 305 same rat model intranasal injection of MSCs resulted not only in the appearance of cells in the 306 olfactory bulb, cortex, hippocampus, striatum, cerebellum, brainstem, and spinal cord, they also 307 decreased the concentrations of a variety of inflammatory cytokines in the lesioned side comparable 308 to levels in the intact hemisphere, and they completely eliminated 6-hydroxydopamine-induced 309 apoptosis (Danielyan et al., 2011) . This study most likely also represents one of the first non-invasive 310 applications of stem cells countervailing a neural disorder. 311
312
Potential pitfalls 313
Many of the aforementioned clinical applications of MSCs bear considerable risks of undesirable 314 outcomes, primarily because there are currently no unique molecular identifiers to specify well-315 defined subpopulations within the heterogenous MSCs set, which actually exert distinct superior 316 activities in a particular medical setting. Dealing with such functional implications, for instance 317 immune suppression triggered by MSCs, could be both benefit as well as detriment. Either 318 supporting or exogenously controlling these particular features needs to be decisively implemented 319 in the standards and guidelines of clinical therapies. By the same token, other phenotypic 320 characteristics of mesenchymal progenitors such as fate specification, tissue-specific homing 321 properties, migration and adhesion abilities are to be considered in this context, yet have so far not 322 been studied in great detail. MSCs, although being a highly appreciated stem cell type for clinical 323 application, do also interact with tumor cells leading either to tumor growth or suppression as 324 reported in several well-documented cases (Klopp, Gupta, Spaeth, Andreeff, & Marini, 2011) . Indeed 325 prospectively designed long-term safety studies are imperative here, as more and better 326 understanding of those mechanisms which govern MSC tumor interaction need to be gained in order 327 to prevent potential tumor growth and/or metastasis (Si, Zhao, Hao, Fu, & Han, 2011) . In the case of 328 MSC-based therapies in SCI patients, direct injection of MSCs into the site of injury may also lead to 329 further neurological impairment, thus highly refined surgical procedures have to be developed in 330 parallel to enhancing the MSC regenerative potential. 331 332
Conclusion and future perspectives: 333
Over the last two decades the suitability and appropriateness of MSCs for clinical applications could 334 be demonstrated, and highly specific therapeutic strategies have been introduced. Besides a myriad 335 of studies carried out in the field of bone, cartilage and cardiac repair, stimulation of tendon 336 regeneration, and also the MSC's potential efficacy for functional restoration of nervous tissue has 337 been exploited, indeed resulting in tempting and promising data. Working along this line, a vastly 338 increasing number of clinical trials using MSCs as the therapeutic agent, are actively pursued or 339 currently being launching. Quite some trials were recently completed and corresponding study 340 results have been reported (Table 3 ). There are however many more studies that have only recently 341
been completed yet as of now results have not been reported as notified at http://clinicaltrials.gov 342 (Table 4) . These outcomes will hopefully shed new lights on the efficacy of MSC-based medical 343 therapies and related approaches, thus certainly more scientifically rewarding information is to be 344 expected for the nearest future. The MELD score was improved at patient 1 and 4, furthermore life quality of all follow-up patients was meliorated (Mohamadnejad et al., 2007) 23 
